Form 4: Artiva Biotherapeutics Director Elizabeth Hougen Granted Stock Options

Artiva Biotherapeutics, Inc. Director Elizabeth L. Hougen was granted 13,750 stock options with an exercise price of $1.61, vesting by June 2026.

Summary

• Elizabeth L. Hougen, a Director of Artiva Biotherapeutics, Inc. (ARTV), acquired 13,750 derivative securities in the form of Director Stock Options.
• The options were granted on June 24, 2025, with an exercise price of $1.61 per share.
• The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
• The Director Stock Options have an expiration date of June 23, 2035.
• Following this transaction, Ms. Hougen beneficially owns 13,750 derivative securities.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of director compensation, indicating standard corporate governance practices and alignment of interests, which is generally neutral to slightly positive as it reflects ongoing board engagement.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a common method for retaining experienced board members and ensuring their commitment to the company's success.

Future Outlook

The shares subject to the option are set to vest in full by June 24, 2026, or earlier, aligning the director's long-term incentives with the company's future performance and strategic goals.

Industry Context

Granting stock options to directors is a standard practice within the biotechnology and pharmaceutical industries. This form of equity compensation is widely used to align the interests of board members with those of shareholders, encouraging long-term value creation and retention of key talent in a highly competitive sector.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of compensation in the biotechnology industry, consistent with corporate governance best practices aimed at aligning director and shareholder interests.
• The exercise price of $1.61 is likely the market price on the grant date, which is standard for 'at-the-money' option grants.
• The vesting schedule, tied to the next annual meeting or a specific date within a year, is typical for director equity awards, reflecting their ongoing service.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment between the director's interests and long-term shareholder value due to equity ownership.
• Management: No direct impact mentioned, but reflects standard compensation practices for board oversight.

Next Steps

• The stock options will vest in full on the earlier of June 24, 2026, or the date of Artiva Biotherapeutics' 2026 annual stockholder meeting.

Key Dates

Recommendation

Keywords

Artiva Biotherapeutics, ARTV, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Elizabeth L. Hougen